the vector is Aedes luteocephalus. Various Culex species are also involved in urban epidemics in Asia.
Epidemiology:
In Africa, Chikungunya virus is transmitted in the savannah & forests of tropical Africa by Aedes mosquito & the vertebrate portion of the cycle is provided by non-human primates such as monkeys or baboons which amplify & maintain virus circulation. 6 In African villages or rural areas these mosquitoes may then infect humans & the substantial viraemia measure suggest that humans, in appropriate setting may contribute to mosquito infection, leading to further virus amplification.
Transmission in Asia follows a different pattern from that scene in Africa, being primarily transmitted from human to human by Aedes aegypti & the human epidemics have all been in urban areas infested with Aedes mosquito. CHIK activity in Asia has been documented since its isolation in Bangkok, Thailand in 1958. A series of epidemics usually lasting a single year have been reported from Sri Lanka & Philippines.
Reasons for re-emergence of Chikungunya infection:
-Absence of herd immunity-susceptible population.
-Viral mutation.
-Increased air travel, tourism.
-Virus never disappeared, simple resurgence.
Current scenario in Bangladesh:
Recently an outbreak of Chikungunya fever has been discovered in Dhaka, Dohar Mortality rate is estimated at 0.4% but in patients aged under one year, it is as high as 2.8% & similarly in those aged more than 50 years, death rate increases.
Incubation period:
It is usually 2-3 days, with a range of 1-12 days.
Clinical Features:
Chikungunya is an acute infection of abrupt onset, characterized by fever & arthralgia, followed by other constitutional symptoms and rash & lasting for a period of one to seven days. 1) Fever: fever rises abruptly often reaching 39 to 40 degree centigrade & accompanied by intermittent shaking chills. This acute phase lasts two to three days. The temperature may remit for one to two days, resulting in a 'saddle -back' fever curve. Chronic joint pains are seen in about 1 in 10 cases of Chikungunya infection. The persistant joint pain may be mistaken for rheumatoid arthritis.
3) Cutaneous manifestation: They are typical with many patients presenting with a flush over the face & trunk, usually followed by a rash generally described as maculo-papular. 9 Sometimes rashes are accompanied by severe itching. In many cases rash marks last for a long time (especially the ones on the face). The trunks & limbs are commonly involved but face, palms & soles may also show lesions.
4) During the acute disease, most patients will have headache.
5) Photophobia & retro-orbital pain may also occur but not severe.
6) Conjunctival infection is present in some cases. 
WHO criteria for Chikungunya diagnosis:
-Clinical criteria: acute onset of fever >38.5°C and severe arthralgia/arthritis not explained by other medical conditions. -Epidemiological criteria: residing or having visited epidemic areas, having reported transmission within 15 days prior to the onset of symptoms. -Laboratory criteria: at least one of the tests mentioned above.
The clinical menifestations of Chikungunya fever resemble those of Dengue fever, laboratory diagnosis is critical to establish the cause of disease & initiate specific public health response.
Three main laboratory tests are used for diagnosing Chikungunya fever:
-Virus isolation.
-Serological tests. for Chikungunya virus in acute phase sera is used in instances where paired sera cannot be collected.
-A positive virus culture supplemented with neutralization is taken as definitive proof for the presence of Chikungunya virus.
-PCR results for E1 & C genome either singly or together constitute a positive result for Chikungunya virus.
Treatment:
-There is no specific treatment for Chikungunya. The illness is usually self-limiting & will resolve with time.
-Main purpose of treatment is the management of fever and pain. For treatment of Chikungunya fever, Paracetamol is given in the first few days. It is only required in cases where fever management is essential.
-Other medical conditions if any must be evaluated before taking any medicines. Other non steroidal medicines such as Tramadol may be taken for pain management.
-Non-aspirin & non-steroidal anti inflammatory drugs are recommended. There is no role of antibiotics & antiviral agents. 12 -Supportive care with rest is indicated during acute joint symptoms. Movement & mild exercise tend to improve stiffness & morning arthralgia, but heavy exercise may exacerbate rheumatic symptoms.
-It is important to maintain a healthy life style to promote early recovery from Chikungunya joint pain. A healthy diet which includes fruits and vegetables and good sleep promotes early recovery.
-In unresolved arthritis refractory to NSAID, Chloroquine 13 is found to be effective.
Prognosis:
-Chikungunya is rarely fatal. Recovery from the disease varies by age. Younger patients recover within 5 to 15 days; middle-aged patients recover in 1 to 2.5 months. Recovery is longer for the elderly.
-However, the chronic joint pain associated with it can substantially reduce the quality of life for a patient.
Vaccine against Chikungunya:
-Currently there are no vaccines available in the market for preventing Chikungunya disease. 14, 15 -However scientists have developed a working vaccine for Chikungunya. The experimental Chikungunya vaccine contains noninfectious virus like particles coated with the same protein that enables Chikungunya virus to pass through cell walls.
-However the vaccine particle doesn't contain the proteins that Chikungunya uses for replication and hence is harmless.
-The vaccine looks like Chikungunya virus to the immune system which in turn produces antibodies against it. From the experiments on monkeys it was found that these antibodies can prevent Chikungunya infection.
-Monkeys were injected with the vaccine and then after 15 weeks they were injected with Chikungunya virus. It was found that the vaccine offered 100% protection from the disease. The next step for this vaccine is human testing.
-In the case of Chikungunya, careful evaluation is required before any vaccination is recommended.
-Chikungunya is relatively a low risk infection and hence vaccine side effects must be compared with the actual risk for Chikungunya infection.
-Obviously in areas where the infection incidence is low and where mosquitoe bites are also low, probably there is no need for a vaccine. So when the Chikungunya vaccine becomes available, it is up to the individuals to take an informed decision.
Prevention & Control:
-There is no vaccine or specific medication available against Chikungunya infection.
-Vector control is thus very important in controlling or preventing Chikungunya transmission. Elimination of breeding sites or source reduction is an effective method of control. Aedes aegypti is typically a container habitat species & breeds primarily in artificial container & receptacles.
-The best way is to encourage people to eliminate the mosquito habitats by emptying water containers once a week & keeping the permanent water containers covered with a tight fitting lid. Adoption of these methods can be encouraged through community based programmes.
-Legislation, strong public advocacy & community involvement can also help in vector control.
-Personal protection like long sleeve clothes, covering oneself fully, use of repellents, window nets play limited but useful role.
-Use of standard case mangement guidelines help in reducing the mortality due to Chikungunya.
